Evidence map›Paper›PMID 35972697›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2022

Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?

Tommaso Ercoli, Michele Tinazzi, Christian Geroin, Enrico Marcuzzo, Roberto Erro, Sofia Cuoco, Roberto Ceravolo, Sonia Mazzucchi, Andrea Pilotto, Alessandro Padovani and 27 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 2 countries.

Tommaso Ercoli *Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Michele Tinazzi *Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy. michele.tinazzi@univr.it.
Christian GeroinNeurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy. christian.geroin@univr.it.ORCID 0000-0001-6095-1930
Enrico MarcuzzoNeurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, P.le Scuro 10, 37134, Verona, Italy.
Roberto ErroCenter for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Sofia CuocoCenter for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Roberto CeravoloCenter for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sonia MazzucchiCenter for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Andrea PilottoNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Luigi Michele RomitoParkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Roberto EleopraParkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Mario ZappiaDepartment G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.
Alessandra NicolettiDepartment G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.
Carlo DallocchioDepartment of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.
Carla ArbasinoDepartment of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.
Francesco BonoBotulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.
Giorgio SpanoBotulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.
Benedetta DemartiniAldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.
Orsola GambiniAldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.
Nicola ModugnoIRCCS Neuromed, Pozzilli, Italy.
Enrica OlivolaIRCCS Neuromed, Pozzilli, Italy.
Laura BonanniDepartment of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio, Chieti-Pescara, Italy.
Alberto AlbaneseDepartment of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Gina FerrazzanoDepartment of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.
Alessandro TessitoreDepartment of Advanced Medical and Surgery Sciences, University of Campania-Luigi Vanvitelli, Naples, Italy.
Leonardo LopianoDepartment of Neuroscience-Rita Levi Montalcini, University of Turin, Turin, Italy.
Giovanna Calandra-BuonauraDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Martina PetraccaMovement Disorder Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Francesca MorganteNeurosciences Research Centre, Molecular and Clinical Sciences Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
Marcello EspositoClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Antonio PisaniIRCCS Mondino Foundation, Pavia, Italy.
Paolo ManganottiClinical Neurology Unit, Department of Medical, Surgical and Health Services, University of Trieste, Trieste, Italy.
Lucia TesolinFunctional Movement Disorders Outpatient Clinic, Clinical Neurology and Stroke Unit, Central Country Hospital, Bolzano, Italy.
Francesco TeatiniFunctional Movement Disorders Outpatient Clinic, Clinical Neurology and Stroke Unit, Central Country Hospital, Bolzano, Italy.
Fabrizio StocchiUniversity and Institute of Research and Medical Care San Raffaele Roma, Rome, Italy.
Giovanni DefazioDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
University of Verona · ITAzienda Ospedaliero Universitario Mater Domini · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITIstituto Neurologico Mediterraneo · ITOspedale di Bolzano · ITUniversity of Cagliari · ITUniversity of Catania · ITUniversity of Milan · ITUniversity of Pisa · ITUniversity of Salerno · ITAgostino Gemelli University Polyclinic · ITFatebenefratelli Hospital · ITFondazione Europea Ricerca Biomedica · ITIRCCS Humanitas Research Hospital · ITIstituto delle Scienze Neurologiche di Bologna · ITSan Raffaele University of Rome · ITSapienza University of Rome · ITUniversity of Brescia · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to assess changes in the body distribution and the semeiology of functional motor disorder (FMD) in patients who reported only one or more than one body site affected at FMD onset. Data were obtained from the Italian Registry of Functional Motor Disorders, which included patients with a diagnosis of clinically definite FMDs. The relationship between FMD features and spread to other body sites was estimated by multivariate Cox regression analysis. We identified 201 (49%) patients who reported only one body site affected at FMD onset and 209 (51%) who reported multiple body sites affected at onset. FMD spread from the initial site to another site in 43/201 (21.4%) patients over 5.7 ± 7.1 years in those with only one site affected at FMD onset; FMD spread to an another body site in 29/209 (13.8%) over 5.5 ± 6.5 years. The spread of FMD was associated with non-motor functional symptoms and psychiatric comorbidities only in the patients with one body site affected at FMD onset. Our findings provide novel insight into the natural history of FMD. The number of body sites affected at onset does not seem to have a consistent influence on the risk of spread. Furthermore, our findings suggest that psychiatric comorbidities and non-motor functional symptoms may predict the spread of FMD symptoms, at least in patients with one body site affected at onset.

Indexed as

Motor DisordersMovement DisordersDemographyHumansFunctional motor disordersFunctional neurological disordersOutcomePhenotypic changeSpread

Identifiers

PMID35972697
PMCPMC9468120
OpenAlexW4292182318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.